In early 2022, the FDA approved the intravitreal injection of faricimab (Vabysmo, Genentech, South San Francisco, CA, USA), a novel bispecific monoclonal antibody that simultaneously targets 2 key pathways: VEGF and angiopoietin-2 (Ang-2), for treatment-naive AMD and Diabetic Macular Edema [9] and later for Retinal Vein Occlusion (RVO, 10). Here, ANGPT2 is linked to retinal vein occlusion.